CELATOR Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CELATOR, and when can generic versions of CELATOR drugs launch?
CELATOR has one approved drug.
There are nine US patents protecting CELATOR drugs.
There are one hundred and thirty patent family members on CELATOR drugs in twenty-six countries and thirty-six supplementary protection certificates in sixteen countries.
Summary for CELATOR
| International Patents: | 130 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for CELATOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,518,437 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 9,271,931 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 10,028,912 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,022,279 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CELATOR Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hungary | S1900047 | ⤷ Subscribe |
| Canada | 2383259 | ⤷ Subscribe |
| Spain | 2909903 | ⤷ Subscribe |
| Hungary | E045978 | ⤷ Subscribe |
| Netherlands | 301016 | ⤷ Subscribe |
| Croatia | P20191683 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CELATOR Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2768484 | C20190039 00312 | Estonia | ⤷ Subscribe | PRODUCT NAME: DAUNORUBITSIIN/TSUETARABIIN;REG NO/DATE: EU/1/18/1308 27.08.2018 |
| 2768484 | 2019041 | Norway | ⤷ Subscribe | PRODUCT NAME: KOMBINASJON AV DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180831 |
| 2768484 | 19C1063 | France | ⤷ Subscribe | PRODUCT NAME: COMBINAISON DE DAUNORUBICINE ET CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
| 2768484 | 2019/054 | Ireland | ⤷ Subscribe | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
| 3300601 | 27/2022 | Austria | ⤷ Subscribe | PRODUCT NAME: KOMBINATION VON DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 (MITTEILUNG) 20180827 |
| 2768484 | CA 2019 00051 | Denmark | ⤷ Subscribe | PRODUCT NAME: KOMBINATION AF DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180827 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
